Liquid biopsies for multiple myeloma in a time of precision medicine

Bruna Ferreira¹ · Joana Caetano² · Filipa Barahona¹ · Raquel Lopes¹ · Emilie Carneiro¹ · Bruno Costa-Silva³ · Cristina João⁴

Received: 20 January 2020 / Revised: 6 March 2020 / Accepted: 11 March 2020 / Published online: 4 April 2020
© The Author(s) 2020

Abstract
Multiple myeloma (MM) is a challenging, progressive, and highly heterogeneous hematological malignancy. MM is characterized by multifocal proliferation of neoplastic plasma cells in the bone marrow (BM) and sometimes in extramedullary organs. Despite the availability of novel drugs and the longer median overall survival, some patients survive more than 10 years while others die rapidly. This heterogeneity is mainly driven by biological characteristics of MM cells, including genetic abnormalities. Disease progressions are mainly due to the inability of drugs to overcome refractory disease and inevitable drug-resistant relapse. In clinical practice, a bone marrow biopsy, mostly performed in one site, is still used to access the genetics of MM. However, BM biopsy use is limited by its invasive nature and by often not accurately reflecting the mutational profile of MM. Recent insights into the genetic landscape of MM provide a valuable opportunity to implement precision medicine approaches aiming to enable better patient profiling and selection of targeted therapies. In this review, we explore the use of the emerging field of liquid biopsies in myeloma patients considering current unmet medical needs, such as assessing the dynamic mutational landscape of myeloma, early predictors of treatment response, and a less invasive response monitoring.

Keywords Multiple myeloma · Liquid biopsy · Biomarkers · Precision medicine

Introduction
Multiple myeloma (MM) is a plasma-cell malignancy characterized by bone lesions that is virtually always preceded by a monoclonal gammopathy of undetermined significance (MGUS) [1, 2]. The diagnosis of multiple myeloma is based on the presence of clinical, biochemical, histopathological, and radiological markers of disease. Biological characteristics of MM as well as patient- and drug-dependent factors, such as health status of the patient and treatment toxicities, dramatically influence survival [3, 4].

To address MM clinical heterogeneity, scoring systems have been developed in order to estimate individual prognosis. The degree of anemia, renal failure, and osteolysis were the first disease-related prognostic biomarkers, included in the Salmon & Durie (SD) staging system. Subsequently, serum albumin and β2-microglobulin levels were incorporated in the International Staging System (ISS), reflecting patient tumor burden, turnover rate, presence of renal impairment, and nutritional and performance status [5]. The prognostic performance of the ISS score was updated by adding high-risk cytogenetics [t(4;14), t(14;16), and del17p determined by interphase fluorescence in situ hybridization] and elevated serum lactate dehydrogenase [6]. More recent, deletions and amplification of chromosome 1 were added as conferring worse prognosis [7–9]. Currently, R-ISS is used primarily for risk stratification of patients with clinical implications with regard to selection of therapy but not in a generalized way.

To determine osteolysis and bone marrow involvement, imaging techniques are currently used. The European Myeloma Network and the European Society for Medical Oncology guidelines have recommended whole-body low-dose computer tomography (WBLDCT) as the imaging
modality of choice for the assessment of MM-related lytic bone lesions. Magnetic resonance imaging is the gold-standard imaging modality for detection of bone marrow involvement, whereas positron emission tomography/computed tomography (PET/CT) provides valuable prognostic data and is the preferred technique to assess response to therapy [10].

In clinical practice, bone marrow (BM) biopsy, mostly performed in one site, is used to access the genetic profile of the disease in MM patients. However, tissue biopsies fail to capture the intratumoral and inter-metastatic genetic heterogeneity, which decrease the accuracy of tests based on them [11]. MM is probably not a single entity and comprises a number of molecular subgroups characterized by a compilation of genomic alterations [12, 13]. Therefore, considering the MM clonal heterogeneity, BM biopsies probably do not reflect the true mutational profile in MM due to sampling bias. Also, BM biopsy’s invasive nature hinders serial clonal monitoring. Accurately measuring tumor burden is also crucial for prognostication. The most recent consensus statement from the IMWG regarding BM PC estimation requires either BM aspiration and/or biopsy. However, PC counts on BM aspirates by conventional morphologic or immunohistochemical analysis may vary significantly due to dilution with peripheral blood and the patchy pattern of PCs infiltration. The development of new markers and approaches to more accurately and quickly assess tumor burden in MM patients would result in better outcomes.

The emergence of several new drugs over the past decades has dramatically improved patient outcomes in MM, extending the median survival by 4 years [4, 14]. Complete response (CR) rates have increased in parallel, establishing the need to develop more sensitive methods to better define depth of response as well as to monitor minimal residual disease (MRD) over time. Measurement of MRD in bone marrow by both next-generation sequencing (NGS) of variable diversity joining (V(D)J) rearrangements or next-generation flow cytometry (NGF) is highly predictive of survival in MM [15, 16] and may be used as a biomarker to adapt treatment strategies [17, 18]. However, serial assessments of MRD involve repeated sampling, which imposes the trauma of repeated BM aspirations. Furthermore, false negative MRD values may be obtained due to BM dilution with blood and sampling bias related with the patchy distribution of clonal plasma cells. A way of capturing tumor heterogeneity and potentially decide upon treatment over the course of time in a minimal invasive method in MM patients may be the use of liquid biopsies.

Liquid biopsies include the sampling and testing of biological fluids, typically blood, for a subset of circulating tumor components. The tumor components that can be tested include, among others, circulating tumor cells (CTC), tumor nucleic acids (such as circulating tumor DNA (ctDNA) and microRNA), and extracellular vesicles (EV). This “tumor circulome” can be used as a source of biomarkers for cancer diagnosis, screening, and prognosis [19]. The FDA already approved liquid biopsies for several cancers. In 2016, liquid biopsies were approved for lung cancer prognostication and for colorectal cancer based on ctDNA content [20, 21]. In MM, liquid biopsies are currently being evaluated in clinical studies such as the Liquid Biopsy Evaluation and Repository Development at Princess Margaret study (NCT03702309), The MMRF Cure Cloud Multiple Myeloma Research Initiative (NCT03657251), and the Study to Assess for Measurable Residual Disease (MRD) in multiple myeloma patients (NCT04108624).

Using new biomarkers to improve prognostic models in MM will certainly lead to the development of risk-adaptive therapeutic strategies improving the outcome of this disease and paving the way towards precision therapy.

**Precision medicine in multiple myeloma**

In MM, genome studies have led to a better understanding of the disease, including its genetic heterogeneity, evolution patterns over time, and identification of potential molecular drivers [22]. This complex molecular biology of MM has been described in several studies [23–29] and includes the observation of dynamic intra-patient sub-clonal heterogeneity [23, 25, 27, 30–34] and appearance of distinct sub-clones along longitudinal sampling [30, 32, 33]. Nevertheless, some genes are recurrently mutated in MM. Mutations affecting the RAS/MAPK pathway, such as KRAS, NRAS, and BRAF, were found to be the most frequently observed pathway mutations in MM detected in approximately 40% of patients [12]. Interestingly, 4–9% of MM patients harbor BRAF mutation at diagnosis, with the BRAF V600E mutation being the most common, with even higher frequency at relapse (up to 18%) [23, 24]. Although preclinical studies have shown the cytotoxic effect of BRAF inhibitors in MM cell lines [35], the evidence on using precision medicine approaches to BRAF mutational status and the efficacy of BRAF inhibitors is scarce [36–38]. Another example of potential use of precision medicine in MM is targeting the Bcl-2 apoptotic pathway. MM cell lines and patient samples, particularly those with t(11:14), have been shown to be particularly sensitive to Bcl-2 inhibitors, making Bcl-2 a potential target in this subtype of myeloma. Although the presence of the t(11:14) is used to be considered a standard risk factor, it is increasingly thought of as an intermediate risk factor in the era of novel agents, conferring worse outcome compared with standard-risk myeloma. Venetoclax is an oral compound designed to specifically inhibit the Bcl-2 protein in cancer cells. The sensitivity to the drug has been correlated to the ratio of Bcl-2 to Mcl-1 and Bcl-XL with high Mcl-1 levels conferring resistance to this drug [39]. In the MM clinical setting, venetoclax has been shown to be well tolerated and effective in different phase I/II trials [40–43]. In order
to better determine efficacy, a phase III trial comparing venetoclax in combination with standard treatment bortezomib-dexamethasone (BELLINI trial—M14-031; NCT02755597) is ongoing. However, in March 2019, the trial was interrupted due to safety concerns related to the higher rate of patient deaths with venetoclax combined with bortezomib (Velcade) and dexamethasone (Vd) (Ven + Bd) compared to placebo plus Vd in patients with relapsed/refractory myeloma. However, patients with t [11, 14] had consistent clinical benefit when treated with Ven + Bd, and a biomarker-driven approach with venetoclax seems appropriate in MM.

The new insight into the genetic landscape of MM provides a valuable opportunity for the implementation of precision medicine approaches, enabling patient profiling and selection of potential targeted therapies. However, there are still many challenges for precision medicine in MM, primarily because there is no unique driver mutation in MM and therefore the design of a selective targeted therapy is unlikely to benefit all patients. On the other hand, assessing the disease complexity at diagnosis and over time using liquid biopsies may provide a less invasive method for dynamic disease monitoring and therapeutic guidance. There would be several advantages to this approach guiding therapy, accelerating therapeutic switch to more effective alternatives, avoiding unnecessary side effects of ineffective treatments, and optimizing dose adjustments.

Here, the potential clinical applications of liquid biopsies are discussed, including CTC, ctDNA, microRNA (miRNA), and extracellular vesicles in MM.

**Circulating tumor cells**

In MM, CTCs are released from the primary tumor into the bloodstream [44], homing again to the BM at different locations in a metastatic dissemination process [45]. Migration of CTCs seems to be an early event in carcinogenesis [46] and since they were first described in 1869 by Ashworth, several studies have provided evidence of their presence in cancer patients [47, 48]. In recent years, they have gained increasing importance because they are minimally invasive indicators that can reveal critical information about the tumor. Indeed, CTCs may have numerous clinical applications, namely in detection, characterization, treatment guidance, and follow-up of cancer patients [49].

Several novel techniques to detect CTCs have emerged, either through nucleic acid-based or cytometric methods [50–53]. The first approach is highly sensitive and relies on the detection of specific DNA or RNA sequences expressed by tumor cells. However, cytometric assays have been proved to be easier to implement and have been privileged to identify and characterize CTCs according to their immune profile, size, and expression of specific markers [47]. Currently, CellSearch is the only FDA-approved technology for extraction and enumeration of CTCs of epithelial origin in the whole blood in specific cohorts of patients with solid cancers, namely breast, prostate, and colorectal carcinomas [54–57]. Despite the low number of cells and morphologic heterogeneity, this system is able to provide an accurate, sensitive, and reproducible way to count CTCs [58]. Still, this is not straightforward for all types of cancer and further development is needed to expand this approach to other neoplasias, such as MM.

Several research groups have tried to improve the tools to detect and characterize CTCs in MM. Foulk and colleagues were able to develop a kit for enumeration and characterization of CTCs by fluorescence in situ hybridization (FISH) and next-generation sequencing (NGS), showing more CTCs in all stages of MM compared to healthy donors. They showed that the number of CTCs in newly diagnosed myeloma patients correlates with other disease characteristics, such as the percentage of PCs in the BM, serum M protein, and International Staging System (ISS) [59]. In another study, Zhang and his team developed a linear and accurate cell-based immunofluorescence assay to distinguish MM CTCs from normal leukocytes based on specific morphological parameters and expression levels of CD138 and CD45 [60].

In a study analyzing the transcriptional profile of CTCs in MM, the gene expression profile of those cells was found to be identical to BM clonal PCs. However, CTCs were shown to have a higher expression of genes involved in key functions, such as inflammatory response, hypoxia, cell cycle, and migration, some of which associated with significantly inferior progression free survival and related to more aggressive disease [61]. Another study reported similar findings at a single-cell level, showing that in half of the patients, the proportion of mutated CTCs was significantly higher than in single cells from BM samples [62]. This suggests that CTCs may provide relevant information regarding sub-clonal assessment in MM, beyond what BM findings show.

Several research groups have been successful in developing new methods to detect CTCs, correlating their numbers and characteristics with an unfavorable prognosis [35, 63, 64]. The number of CTCs was found to be a predictor of survival in patients with both newly diagnosed [65] and relapsed disease [66]. Interestingly, high levels of CTCs in smoldering MM (SMM) were associated with a high risk of progression to overt MM in the first 2–3 years after diagnosis [67]. Recently, using next-generation flow (NGF) method developed by EuroFlow, Sanoja-Flores et al. showed that CTCs in PB at diagnosis are associated with poorer outcome of both MGUS and MM patients [15].

**Cell-free circulating tumor DNA**

Noninvasive assessment of tumor DNA is possible with cell-free circulating tumor DNA as well as from circulating tumor
cells. In contrast to the circulating intact tumor cells in blood, ctDNA consists of small fragments of nucleic acids extracted from the plasma or serum. The cancer-derived fragments may be identified if they contain tumor-specific mutations or other genetic aberrations. Both quantitative and qualitative information can be obtained from ctDNA analysis. Due to the short half-life of DNA (approx. 2.5 h), ctDNA quantification provides a real-time snapshot of tumor bulk. Qualitative information stems from the description of genetic alterations found in ctDNA, which may be assessed overtime to show clonal evolution in MM. [68]

Deep sequencing of ctDNA from MM patients is a technique with a high sensitivity and has recently been demonstrated to recapitulate mutational profiles of matched BM aspirates [69]. Analysis of plasma-derived ctDNA as an adjunct to BM biopsy, for mutational characterization and tracking disease progression, is currently possible using droplet digital PCR [70]. Kis et al. reported that sequencing of ctDNA enables the analysis of sub-clonal hierarchies, reflecting tumor profiling with high levels of concordance with matched BM aspirations [69]. Analysis of plasma-derived ctDNA as an adjunct to BM biopsy, for mutational characterization and tracking disease progression, is currently possible using droplet digital PCR [70].

MiRNAs are small sequences of RNA, approximately 25 nucleotides long, found in various body fluids [80, 81]. In blood, miRNAs circulate stably bound to proteins, high-density lipoproteins, within extracellular vesicles such as exosomes or in apoptotic vesicles [82, 83]. They regulate gene expression by either promoting messenger RNA (mRNA) degradation or repressing its translation, playing crucial roles in a variety of physiological- and cancer-related processes, including cell motility, differentiation, proliferation, and apoptosis [84]. It is not yet certain whether circulating miRNAs are passively released into the circulation from apoptotic and necrotic cells or if they are specifically secreted, for instance, in exosomes [85, 86].

Methods for measuring circulating miRNAs are not yet validated or standardized. Current strategies begin with extraction and purification of circulating miRNAs from plasma or serum, followed by screening and identification of sequences of interest using micro-arrays, subsequently confirmed and validated by RT-PCR. NGS, although potentially useful for discovering new miRNAs, is more expensive and time-consuming and needs further development for this application.

Several groups have identified different miRNA with important roles in MM pathogenesis and progression, providing a potential tool for distinguishing MM patients from healthy controls and MGUS patients (Table 1). In MM, miRNAs exhibited similar expression patterns in peripheral blood and BM aspirates [87], which makes them good candidates for biomarkers of disease both at diagnosis, during treatment, and relapse.

Thus far, no single miRNA was shown to predict the evolution from MGUS to MM. However, the combination of miR-1246 and miR-1308 was able to distinguish between MGUS and MM [92]. Also, in MGUS patients, miR-92a plasma level was significantly higher compared to MM patients,
but there was no significant difference between patients with smoldering disease and MGUS [91].

MiRNAs have been reported as a prognostic tool and correlate with survival outcomes in MM [80, 92–94, 96, 97].
Concerning the response to treatment, miR-92a plasma levels were described to return to baseline in patients achieving CR but not in those achieving only partial response (PR) or very good partial response (VGPR) [91]. Patients with high serum expression levels of miR-17-92 cluster had shorter PFS compared to those with low level expression [98], suggesting that this cluster is associated with poor prognosis in MM. Low level miR-483-5p was associated with better PFS [95]. Multivariate analysis revealed that miR-19a was a significant predictor of shorter PFS and OS [94]. Expression of some miRNAs dynamically change in MM patient’s plasma/serum during disease progression, and so continuous detection of miRNA levels in blood could be used to monitor disease status and assess prognosis. High miR-34a and low let-7d expressions were observed in relapsed MM patients compared to levels in patients at the time of diagnosis [91].

There seems to be a relation between changes in miRNA pattern of expression and specific genetic abnormalities, particularly cytogenetic abnormalities associated with poor prognosis such as del(13q14), 1q21 amplification, or t(4;14) [93]. Deregulation of target genes of miRNAs upregulated in t(4;14) MM genetic subtype seems to promote oncogenesis by modulating the expression of proteins associated with cellular growth and proliferation (Table 2).

As an example, the gene for miR-744 is in the 17p12 region where various tumor-related genes are closely situated (TP53, BRCA1, and FBXO4) and deletions at chromosome 17p13.1-17p12 were previously associated with poor survival in cancers [100]. Moreover, downregulation of several miRNAs resulted in overexpression of cyclin D2 (CCND2) as observed in t(4;14) and t(4;16), suggesting for the first time that miRNA expression patterns in MM were correlated with protein expression patterns in specific genetic abnormalities [101].

Furthermore, targeting deregulated miRNA in MM might be a promising therapeutic approach. Among the potential targets, miR-21 is upregulated in MGUS and MM, promoting survival and progression. Interleukin-6 is responsible for regulating miR-21 through Stat-3 activation, a central pathway for MM cell growth and drug resistance. Tumor suppressor genes such as PTEN, BTG2, and Rho-B are targeted by miR-21. Upregulation of their expression with oligonucleotide inhibitors of miR-21 may result in anti-tumor activity against MM [102].

Additionally, aberrant expression of several miRNAs has been observed in drug-resistant myeloma cell lines, suggesting that deregulated miRNAs might be involved in drug resistance of MM cells (Table 3).

**Extracellular vesicles**

Extracellular vesicles (EVs) are bilayer lipid particles naturally released from all cells [106]. Major roles for EVs have been proposed in numerous physiological and pathological processes. In cancer, EVs are emerging as novel players in intercellular communication that transfer cargo molecules (including RNA, DNA, proteins, among others) that, when up taken by target cells, can influence their behavior [107]. EVs derived both from MM cells and bone marrow stromal cells (BMSC) have been found to intervene in key processes of MM such as tumor progression [108], immunosuppression [109], osteogenesis [110, 111], angiogenesis [112–114] procoagulant activity [115], and drug resistance [116–118] through the transfer of proteins and regulation of miRNA expression in the bone marrow microenvironment.

Since EVs can be found in several biological fluids, such as peripheral blood [119], it makes them an attractive biomarker in liquid biopsies. In the clinical setting, we and others have shown that MM patients have different EV miRNA expression levels and protein content compared to healthy subjects [116, 120]. Moreover, the content analysis of these EVs has been used as prognostic factor [116] and to predict therapy resistance in MM patients [117].

Because EVs are a new field of research, several challenges remain, including the nomenclature of distinct subtypes of EVs, the lack of good established markers, and diversity of separation protocols [107]. In an attempt to improve standardization to the field, the International Society for Extracellular Vesicles recently updated their guidelines for the analysis of EVs and the reporting of the results. For instance, special considerations for EV separation from biological fluids such as blood derivates need to be considered and technical factors should be recorded for reproducibility. Factors as such as donor age, biological sex, diet, specific diseases, and medications, among many others, may affect circulating EV [106]. On the other hand, technical factors including pre-analytical

---

**Table 2** Correlation of miRNA and cytogenetic abnormalities

| miRNA      | Upregulation/Downregulation | Cytogenetic abnormalities                  | Reference |
|------------|-----------------------------|------------------------------------------|-----------|
| miR-19a    | Downregulation              | del(13q14) and 1q21 amplification        | [94]      |
| miR-99b    | Upregulation                | t(4;14)                                  | [90]      |
| miR-211    | Downregulation              | del(13q)                                 | [90]      |
| let-7e and miR-744 | Downregulation             | del(13q)                                 | [93]      |
| miR-744    | Downregulation              | 1q12 amplification or t(4;14)             | [93]      |
| miR-15 and miR-16 | Downregulation/ Loss       | del(13q14)                               | [99]      |
variables such as source of EV, storage conditions, manipulation of the source material, and experimental conditions can affect EV recovery [106].

Finally, one should take into account that, according to these guidelines, complete isolation of EVs from other entities is currently an unrealistic goal. Separation of EVs from other non-EV components can be achieved to various degrees by the different techniques. The degree of EVs purification depends on the experimental question and the need to attribute a function to vesicles as compared with other particles [106].

Precise characterization of RNA, DNA, and protein components of EVs and non-vesicle compartments are needed to clarify the heterogeneity of EVs. This is crucial to identify biomarkers and avoid potential overlap when using such components as liquid biopsies. Recently, Jeppesen et al. demonstrated that extracellular double-stranded DNA (dsDNA) and histones are not associated with exosomes or any EVs but instead released as non-vesicular entities, proposing a new model for active secretion of extracellular DNA through autophagy and multi-vesicular-endosome-dependent but exosome-independent mechanism [121].

In MM, several studies have investigated EVs as an active vehicle for molecules that can modulate the BM microenvironment. In 2013, Roccaro et al. demonstrated that EVs derived from BM mesenchymal stromal cells (BM-MSCs) of MM patients have different functional activity compared to healthy donors, showing higher contents of oncogenic proteins, cytokines, and proteins that are regulators of adhesion and migration [108]. Considering bone disease, Faict et al. demonstrated in vivo that MM-derived EVs could induce osteolysis in a similar pattern as the MM cells themselves [110]. Interestingly, the authors showed that blocking EVs secretion using the sphingomyelinase inhibitor GW4869 not only increased cortical bone volume but also sensitized the myeloma cells to bortezomib, leading to a stronger anti-tumor response when GW4869 and bortezomib were combined. On the other hand, Zarfati et al. showed that EVs released from MM cell lines after treatment with bortezomib promoted suppression of angiogenesis by decreasing proliferation and migration of endothelial cells [114], suggesting that EV-mediated cell to cell communication in MM BM microenvironment may influence mechanisms of drug resistance.

In the clinical setting, Manier et al. showed that the use of miRNAs contained in circulating EVs predict poor prognosis in newly diagnosed MM patients [116]. These authors analyzed EVs isolated from serum samples from 156 patients with newly diagnosed MM uniformly treated with bortezomib and dexamethasone and showed that let-7b and miR-18a were significantly associated with poor PFS and overall survival (OS), independently of the International Staging System and cytogenetics. Moreover, Zhang et al. showed that a downregulation of exosomal miR-16-6p, miR-15a-5p, miR-17-5p, miR-20a-5p, and miR-15a-5p was found in patients resistant to bortezomib [117]. In another study, Sun et al. reported that EV miR-214 secreted by osteoclasts is transferred to osteoblasts, inhibiting their activity. Circulating miR-214 levels were found to be significantly increased in EVs from osteoporotic patients in comparison to the non-osteoporotic ones, suggesting a potential use of EVs as new biomarkers for MM-related bone disease.

Since MM is a multifocal disease with spatial and genetic heterogeneity, one can hypothesize that the cellular crosstalk through EVs can be implicated in disease behavior, sustaining potential transfer of mechanisms of progression or drug resistance between cells in different niches. In the future, by having access to circulating EVs in MM patients, it will be possible to have a new and dynamic insight into this disease, in a minimally invasive way.

### Discussion and conclusions

Tumor biopsy is currently the gold standard for assessing somatic alterations, but this approach is invasive and does not
consider tumor heterogeneity. Liquid biopsies may be considered a better alternative because of their noninvasive, rapid, precise, and almost real-time attributes. However, before being applied to the clinical setting, these methodologies need to be harmonized and validated in well-powered and well-designed studies. One of the primary prerequisites is the incorporation of these analyses in the follow-up strategy and checking of the concordance with gold-standard detection methods as imaging, M protein concentration, and biopsy histology.

In this review, an overview of the use of the emerging new field of liquid biopsies in myeloma patients is provided considering current unmet medical needs such as better access to the dynamic mutational landscape of myeloma, early predictors of treatment response, and disease monitoring over time in a less invasive way. These biomarkers add to the recent insights into the genetic landscape of MM, providing a valuable opportunity to implement precision medicine approaches with the objective of enabling better patient profiling and selection of targeted therapies. Table 4 summarizes some of the advantages and limitations of the different approaches here analyzed.

As aberrant miRNA expression is a common feature in a variety of cancers, including MM, these molecules offer exciting new opportunities for the discovery and validation of novel therapeutic targets. The published evidence on miRNA as potential biomarkers for MM and on data establishing the role of different miRNAs as prognostic factors in MM was reviewed. Whether or not specific miRNAs play a significant role in pathogenesis or treatment needs further investigation, including long-term clinical data, both in clinical trials and in real life. Some of the data on miRNAs refer to specific miRNAs found in EVs. Several studies have explored the biological function of EVs and their potential clinical use in MM patients. Because EVs can be measured through minimally invasive procedures and their contents are relevant as disease biomarkers, they have a strong potential to be translated into clinical practice [122]. As potential new biomarkers in MM, EVs may offer the advantage of assessing the cellular crosstalk between tumor cells and surrounding cells, including the potential interception of intercellular communication before onset of clinical symptoms, response to treatment, patient follow up, and disease aggressiveness. Additionally, both

Table 4

| Table 4 | Comparison between the different approaches to liquid biopsies |
|---------|-------------------------------------------------------------|
| **Advantages** | **Limitations** |
| **CTCs** | - Several methods available for enumeration and characterization of CTCs (PCR, flow cytometry, image-based immunomagnetic, microchip)  
- Potential to consistently enumerate, track, and characterize CTCs throughout the course of disease  
- Possibility of assessing molecular characteristics of CTCs for clinical decision-making  
- Could be cultured to evaluate drug resistance in vitro or in vivo and used for functional assays |
| - Low number in blood requires very sensitive and robust methods  
- High sample volume or sample enrichment approaches needed to increase likelihood of detection  
- Costly, specifically if background blood profiling is needed  
- Lacks standardization and reproducibility  
- Need for large-scale clinical data for validation in clinical practice |
| **ctDNA** | - Can be sampled regularly to monitor response to treatment, clonal evolution, and acquisition of resistance  
- Wide range of techniques for analysis available (NGS, digital droplet PCR)  
- Represents tumor heterogeneity (genetic alterations, level of genetic instability, number and properties of sub-clones)  
- Found in larger quantities in blood than CTCs  
- More stable than miRNA  
- Analysis performed in other body fluids than blood (urine, CSF) |
| - Concentration of ctDNA variable among patients and according to type, location, and stage of disease  
- Half-life of ctDNA still unclear  
- Source of ctDNA not clear (lytic, apoptotic tumor cells or CTCs)  
- Presence of background of non-altered circulating free DNA (cfDNA) from other cellular sources  
- Requires previous knowledge of target of interest  
- Need to control preanalytic aspects (rapid processing of samples to avoid cell death and release of ctDNA not reflecting tumor cells)  
- Need for large-scale clinical data for validation in clinical practice  
- Sampling methods could impact miRNA detection  
- Level of miRNA in patients and healthy individuals overlap (increased possibility of false negative or positive diagnosis)  
- Altered expression patterns of the same miRNA in various types of cancers  
- No single miRNA biomarker but a combination needed for clinical application  
- Lack of standardization protocols  
- Circulating EVs can be influenced by several patient factors  
- Time-consuming  
- High cost  
- Heterogeneity of EV recovery population between methods  
- Need for correlation with clinical data |
| **miRNA** | - Stable in healthy individuals (age, gender, body mass) vs altered expression in disease  
- Various sources (plasma, serum, urine, saliva)  
- Sensitive detection methods for miRNAs (sensitive biomarker)  
- Dynamic expression pattern associated with stage and progression of disease  
- Potential target for MM treatment |
| - No single miRNA biomarker but a combination needed for clinical application  
- Lack of standardization protocols  
- Circulating EVs can be influenced by several patient factors  
- Time-consuming  
- High cost  
- Heterogeneity of EV recovery population between methods  
- Need for correlation with clinical data |
| **EV** | - Easy to access  
- Present in several body fluids  
- Longevity and stability within circulation  
- Potential biomarker for early detection and prognosis of MM  
- Potential drug delivery vehicle and vaccine  
- Potential target for MM treatment |
| - Sampling methods could impact miRNA detection  
- Level of miRNA in patients and healthy individuals overlap (increased possibility of false negative or positive diagnosis)  
- Altered expression patterns of the same miRNA in various types of cancers  
- No single miRNA biomarker but a combination needed for clinical application  
- Lack of standardization protocols  
- Circulating EVs can be influenced by several patient factors  
- Time-consuming  
- High cost  
- Heterogeneity of EV recovery population between methods  
- Need for correlation with clinical data |
miRNAs and EVs constitute potential targets for therapeutic intervention. However, one should consider the current technical limitations of EV isolation, including lack of standardization protocols. Current methods for EVs isolation are still very time-consuming impairing their use in the clinical practice. More sensitive and user-friendly methods of EVs analysis such as nanoparticle flow cytometry are currently being validated and will hopefully overcome this. Additionally, new potential targets for MM diagnosis and monitoring are being evaluated. Tumor-educated blood platelets (TEPs) were recently identified as noninvasive biomarkers by sequestering EV-derived RNAs and proteins, therefore providing information on the presence, location, and molecular characteristics of cancers [123]. Platelets are fundamental components of the tumor microenvironment that mediate crucial steps in tumor progression. Takagi et al. recently demonstrated that platelets derived from MM patients are highly activated and correlated with disease status. Their work showed that platelet-mediated upregulation of IL-1β through induction of IL-6, a growth and survival factor for MM cells, is critical for MM proliferation [124]. These preclinical data suggest that not only TEP RNA could complement biomarkers used for liquid biopsy diagnosis but also disease progression might be delayed by early targeting platelet-tumor interaction in MM via platelet-regulating agents.

Future studies taking into consideration larger cohorts of patients, different disease stages, and various therapeutic settings are required to further explore the relevance of liquid biopsies in MM, both in the clinical and investigational settings.

Compliance with ethical standards

Conflict of interest The authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Landgren O, Kyle R, Pfeiffer RM, Katzmann J, Caporaso NE, Richard B, et al (2014) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. 113(22):5412–7
2. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Clin Trialsand Obs 113(22):5418–5422
3. João C, Coelho I, Costa C, Esteves S, Lucio P. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma—real life experience of a tertiary cancer center
4. Kumar SK, Dispensieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, et al. (2014) Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia [Internet]. 28:1122–8. Available from: www.nature.com/leu
5. Sonneveld P, Westin J, Shimizu K, Morgan G, Greipp PR, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23(15):3412–3420
6. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L et al (2015 Aug) Revisited international staging system for multiple myeloma: a report from international myeloma working group. J Clin Oncol 33(26):2863–2869
7. Nahi H, Vatsseen TK, Lund J, Heeg BMS, Preiss B, Alici E, Møller MB, Wader KF, Møller HE, Groseth LA, Østergaard B, Hai HY, Holmberg E, Gaftan G, Waage A, Abbildagard N (2016 Jan 1) Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. Eur J Haematol 96(1):46–54
8. Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B (2015 Jun 11) Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma. Blood. 125(24):3756–3759
9. Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. (2016) Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Vol. 127, Blood. American Society of Hematology: p. 2955–62
10. Zamagni E, Taccletti P, Cavo M (2019) Imaging in multiple myeloma: how? When? Blood. 133(7):644 LP – 651
11. Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C et al (2017 Dec) Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun 8(1):268
12. Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM (2016 Aug) Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14:100
13. Morgan GJ, Walker BA, Davies FE (2012) The genetic architecture of multiple myeloma. Vol. 12, Nature Reviews Cancer. p. 335–48
14. Sun T, Wang S, Sun H, Wen J, An G, Li J (2018 Jan) Improved experience of a tertiary cancer center
15. Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, García-Sánchez O, Böttcher S et al (2017 Jan) Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leuk Lymphoma 59(1):49–58
16. Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien M-L, et al. (2018) Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 123(23):2456 LP – 2464
17. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kafratis E, Boccadoro M, Orlovska R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H (2016 Aug)
International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346.

18. Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM (2017 Jan) Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. JAMA Oncol 3(1):28–35.

19. De Rubis G, Rajeev Krishnan S, Bebawy M (2019 Mar) Liquid biopsies in cancer diagnosis, monitoring, and prognosis. Trends Pharmacol Sci 40(3):172–186.

20. Kwaśniz D (2017) The first liquid biopsy test approved. Is it a new era of mutation testing for non-small cell lung cancer? Ann Transl Med Vol 5, No 3 Ann Transl Med (Focus “Treatment Hepat B”) 2017.

21. Wills B, Gorse E, Lee V (2018) Role of liquid biopsies in colorectal cancer. Curr Probil Cancer [Internet]. [cited 2019 Sep 12];42(6):593–600. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30268335.

22. Robiou du Pont S, Cleynen A, Fontan C, Attal M, Munshi N, Corre J, Avet-Loiseau H (2017 Mar) Genomics of multiple myeloma. J Clin Oncol 35(9):963–967.

23. Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I et al (2014 Jan) Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun 5:2997.

24. Walker BA, Boyle EM, Wardell CP, Murison A, Begum DB, Dahir NM, Proszek PZ, Johnson DC, Kaiser MF et al (2015 Aug) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33(33):3911–3920.

25. Walker BA, Wardell CP, Melchor L, Brioli A, Johnson DC, Kaiser MF et al (2013 Jul) Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 28:384.

26. Bolli N, Li Y, Sathiaselvan V, Raine K, Jones D, Ganly P et al (2016) A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma. Blood Cancer J 6:e467.

27. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al (2011 Mar) Initial genome sequencing and analysis of multiple myeloma. Nature. 471:467.

28. Gould J, Vij R, Fonseca R, Hofmeister CC, Perkins LM, Kumar S et al (2014) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91–967.

29. Hoang PH, Dobbsin SE, Cornish AJ, Chubb D, Law PJ, Kaiser M, Houliston RS (2018) Whole-genome sequencing of multiple myeloma reveals oncogenic pathways are targeted somatically through multiple mechanisms. Leukemia. 32(11):2459–2470.

30. Keats JJ, Chesi M, Egan JB, Garibbi VM, Palmer SE, Braggio E et al. (2012) Clonal competition with alternating dominance in multiple myeloma. Blood. :120(5):1067 LP – 1076.

31. Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. (2016) Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 128(13):1735 LP – 1744.

32. Egan JB, Shi C-X, Tembe W, Christoforides A, Kordoglu A, Sinari S, et al. 2012 Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genome initiating events, evolution, and clonal tides. Blood. Aug;120(5):1060 LP – 1066.

33. Melchor L, Brioli A, Wardell CP, Murison A, Potter NE, Kaiser MF et al (2014 Jan) Single-cell genetic analysis reveals the composition of initiating clones and phylogenetic patterns of branching and parallel evolution in myeloma. Leukemia. 28:1705.

34. Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M et al (2018) Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 32(12):2636–2647.

35. Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksga, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M, Multiple Myeloma Research Consortium, Getz G, Golub TR (2014 Jan) Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell 25(1):91–101.

36. Raab MS, Lehners N, Xu J, Ho AD, Schirmacher P, Goldschmidt H, et al. (2016) Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition. Blood. 127(17):2155 LP – 2157.

37. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay J-Y, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzi M, Sirzen F, Veronese ML, Taberner J, Baselga J (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373(8):726–736.

38. Bohn OL, Hsu K, Hyman DM, Pignataro DS, Ginalt S, Teruya-Feldstein J (2014 Apr) BRAF V600E mutation and clonal evolution in a patient with relapsed refractory plasma cell leukemia with plasmablastic differentiation. Clin Lymphoma, Myeloma Leuk 14(2):e65–e68.

39. Wu J, Ross J, Peale F V, Shaughnessy JD, Van Laar RK, Morgan GJ, et al. (2016) A Favorable BCL-2 Family expression profile may explain the increased susceptibility of the t(11;14) multiple myeloma subgroup to single agent venetoclax. Blood. :128(22):5613 LP – 5613.

40. Kumar S, Kaufman JL, Gasparetto C, Mikhail J, Vij R, Pegourie B, et al. (2017) Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood.;130(22):2401 LP – 2409.

41. Kaufman JL, Gasparetto CJ, Mikhail J, Moreau P, Touzeau C, Vij R, et al. (2017) Phase 1 study of venetoclax in combination with dexamethasone as targeted therapy for t(11;14) relapsed/refractory multiple myeloma. Blood. 130(Suppl 1):3131 LP – 3131.

42. Moreau P, Chanan-Khan A, Roberts AW, Agarwal AB, Facon T, Kumar S, et al. (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. Blood-2017-06-788323.

43. Costa LJ, Stadtmauer EA, Morgan G, Monohan G, Kovacsovics F, et al. (2014) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33(33):3911–3920.

44. Moreau P, Chanan-Khan A, Roberts AW, Facon T, Kumar S, et al. (2017) Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM. Blood. Blood-2017-06-788323.

45. Costa LJ, Stadtmauer EA, Morgan G, Monohan G, Kovacsovics F, et al. (2014) Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. J Clin Oncol 33(33):3911–3920.

46. Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, Attal M et al (2018) Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 32(12):2636–2647.

47. Krebs MG, Hou J-M, Ward TH, Blackhall FH, Dice C (2010) Circulating tumour cells: their utility in cancer management and predicting outcomes. Ther Adv Med Oncol 2(6):351–365.

48. Sondling KE, Lowe AC (2019) Circulating tumor cells: overview and opportunities in cytology. Adv Anat Pathol 26(1):56–63.

49. Krebs MG, Metcalfe RL, Carter L, Brady G, Blackhall FH, Dice C (2014) Molecular analysis of circulating tumour cells — biology and biomarkers. Nat Rev Clin Oncol 11(3):1–16.
50. Alunni-Fabbroni M, Sandri MT (2010) Circulating tumour cells in clinical practice: methods of detection and possible characterization. Methods. 50(4):289–297

51. Pantel K, Aixa-Panabieres C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6:339–351

52. Paterlini-Brechot P, Benali NL (2007) Circulating tumor cells (CTC) detection: clinical impact and future directions. Cancer Lett 253(2):180–204

53. Farace F, Massard C, Vimon N, Drusch F, Jacques N, Billiot F et al (2011 Aug) A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 105:847

54. Miller MC, Doyle GV, Terstappen LWMM (2010) Significance of circulating tumor cells detected by the CellSearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:1–8

55. Cristofanilli M, Bud G, Ellis MJ, Stepeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351(8):781–791

56. Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen LW. (2008 Jul) Relationship of circulating tumor cells to tumor progression, response-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol 26(19):3213–3221

57. de Bonis JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. (2008) Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 14(19):6302 LP – 6309

58. Sun Y-F, Yang X-R, Zhou J, Qiu SJ, Fan J, Xu Y (2011 Jun) Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. J Cancer Res Clin Oncol 137(8):1151–1173

59. Foulk B, Schaffer M, Gross S, Rao C, Smirnov D, Connelly MC et al. (2018) Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders. Br J Hematol 180:71–81

60. Zhang L, Beasley S, Prigozhina NL, Higgins R, Ikeda S, Lee FY, et al. (2019) Transcriptomic profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination. Blood. 122(22):3591–3597

61. García J, Paiva B, Paino T, Sayagues J, Garayoa M, San-segundo L, Mota I (2019 Aug 19);106(7):2276–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/31596151

62. Gonsalves WI, Morice WG, Rajkumar V, Gupta V, Timm MM, Dispenzieri A, et al. (2014) Quantification of clonal circulating plasma cells in relapsed multiple myeloma. Br J Haematol [Internet]. [cited 2019 Aug 19];167(4):500–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25113422

63. Bianchi G, Richardson PG, Anderson KC (2015) Title Page Bianchi et al. Promising therapies in myeloma promising therapies in multiple myeloma. Blood First Ed Pap [Internet]. Available from: www.bloodjournal.org

64. Mithraprabhu S, Spencer A (2017) Circulating tumour DNA analysis in multiple myeloma. Vol. 8, Oncotarget. Impact Journals LLC; p. 90610–1

65. Gerber B, Manzoni M, Spina V, Bruscaggin A, Lionetti M, Fabris S, Barbieri M, Ciceri G, Pompa A, Forestieri G, Lerch E, Servida P, Bertoni F, Zucchi E, Ghielmini M, Corteletti A, Cavalli F, Stussi G, Baldini L, Rossi D, Neri A (2018 Jun) Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. Haematologica. 103(6):e245–e248

66. Rustad EH, Coward E, Skytsoen ER, Misund K, Holien T, Stendal T, Børset M, Beisvang V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017 Jul) Monitoring multiple myeloma by quantification of recurrent mutations in serum. Haematologica. 102(7):1266–1272

67. Kis O, Kaedbye R, Chow S, Danesh A, Dowar M, Li T et al (2017 May) Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates. Nat Commun 8:15086

68. Weinhold N, Chavan SS, Heuck C, Stephens OW, Tytarenko R, Bauer M et al (2015) High risk multiple myeloma demonstrates marked spatial genomic heterogeneity between focal lesions and random bone marrow; implications for targeted therapy and treatment resistance. Blood:126(23)

69. Hohaus S, Giacheli M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D’Alò F, Martini M, Larocca LM, Voso MT, Leone G (2009 May) Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol 20(8):1408–1413

70. Schwarz AK, Stanulla M, Cario G, Florio T, Sutton R, Möricke A, Anker P, Stroun M, Welte K, Bartram CR, Schrappe M, Schrauder A (2009) Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 88(9):897–905

71. Leon SA, Shapiro B, Cario G, Florio T, Sutton R, Möricke A, Anker P, Stroun M, Welte K, Bartram CR, Schrappe M, Schrauder A (2009) Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 88(9):897–905

72. Leon SA, Shapiro B, Cario G, Florio T, Sutton R, Möricke A, Anker P, Stroun M, Welte K, Bartram CR, Schrappe M, Schrauder A (2009) Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 88(9):897–905

73. Pugh TJ (2018) Circulating tumour DNA for detecting minimal residual disease in multiple myeloma. Semin Hematol 55(1):38–40

74. Mazzotti C, Buisson L, Maheo S, Perrot A, Chretien M-L, Leleu Y, et al. (2010) The microRNA spectrum in 12 body fluids; identification of a microRNA profile in multiple myeloma. Blood Adv. 2(21):2811 LP – 2820

75. Tissing H, et al. (2008) Circulating tumor cell detection: clinical impact and future directions. Cancer [Internet]. Available from: www.bloodjournal.org

76. Oberle A, Brandt A, Voigtlaender M, Thiele B, Radloff J, Tilling M, et al. (2015) High risk multiple myeloma demonstrates marked spatial genomic heterogeneity between focal lesions and random bone marrow; implications for targeted therapy and treatment resistance. Blood:126(23)

77. Hoehn M, Giacheli M, Massini G, Mansueto G, Vannata B, Bozzoli V, Criscuolo M, D’Alò F, Martini M, Larocca LM, Voso MT, Leone G (2009 May) Cell-free circulating DNA in Hodgkin’s and non-Hodgkin’s lymphomas. Ann Oncol 20(8):1408–1413

78. Schwartz AK, Stanulla M, Cario G, Florio T, Sutton R, Möricke A, Anker P, Stroun M, Welte K, Bartram CR, Schrappe M, Schrauder A (2009) Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 88(9):897–905

79. Leon SA, Shapiro B, Cario G, Florio T, Sutton R, Möricke A, Anker P, Stroun M, Welte K, Bartram CR, Schrappe M, Schrauder A (2009) Quantification of free total plasma DNA and minimal residual disease detection in the plasma of children with acute lymphoblastic leukemia. Ann Hematol 88(9):897–905

80. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. (2010) The microRNA spectrum in 12 body fluids; Available from: http://www.clinchem.org/content/
81. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the MicroRNA spectrum between serum and plasma. PLoS One

82. Mittelbrunn M, Gutiérrez-Vázquez C, Villarroyo-Beltri C, González S, Sánchez-Cabo F, González MA, et al (2011) Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun

83. Jaiswal R, Luk F, Gong J, Mathys JM, Grau GER, Beawby M (2012) Microparticle conferred microRNA profiles - implications in the transfer and dominance of cancer traits. Mol Cancer

84. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Parkin RK, et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Vol. 105, PNAS

85. Turchinovich A, Weiz L, Burwinckel B (2012) Extracellular miRNAs: the mystery of their origin and function. Trends Biochem Sci

86. Ohshima K, Inoue K, Fujiwara A, Hatakayama K, Kanto K, Watanabe Y et al (2010) Let-7 microRNA family is selectively secreted into the extracellular environment via exosomes in a metastatic gastric cancer cell line. PLoS One

87. Pichiorri F, Suh S-S, Ladetto M, Drandi D, et al (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci

88. Sevcikova S, Kubiczkova L, Sedlarikova L, Slaby O, Hajek R (2012) Extracellular microRNAs: the mystery of their origin and function. Trends Biochem Sci

89. Yu J, Qiu X, Shen X, Shi W, Wu X, Gu G, et al. (2014) miR-202 expression concentration and its clinical significance in the serum of multiple myeloma patients. Ann Clin Biochem

90. Huong JJ, Yu J, Li JY, Liu YT, Zhong RQ (2012) Circulating microRNA expression is associated with genetic subtype and survival of multiple myeloma. Med Oncol

91. Yoshizawa S, Ohyashiki JH, Ohyashiki M, Umezui T, Suzuki K, Inagaki A, et al. (2012) Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders. Blood Cancer J

92. Jones CI, Zabolotskaya MV, King AJ, Stewart HJS, Horne GA, Jones CI, et al. (2011) MiR-15a, MiR-16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma. Oncotarget. 10:6;35(35)

93. Kubiczkova L, Kryukov F, Slaby O, Dementyeva E, Jarkovsky J, Kubiczkova L, et al (2014) Circulating serum microRNAs as novel diagnostic biomarkers for use in multiple myeloma. Br J Cancer

94. Jones JC, Zabolotskaya MVA, King AJ, Stewart HJS, Horne GA, Chevassut TJ et al (2012) Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. Br J Cancer

95. Kryukov F, Slaby O, Slaby O, Dementyeva E, Jarkovsky J, Kubiczkova L, et al (2014) Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. Haematologica

96. Hao M, Zang M, Wendlandt E, Xu Y, An G, Dong G, et al. (2015) Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer

97. Qu X, Zhao M, Wu S, Wu Y, Xu J, Xu J, et al. (2014) Circulating microRNA 483-5p as a novel biomarker for diagnosis survival prediction in multiple myeloma. Med Oncol

98. Navarro A, Diaz T, Tovar N, Pedrosa F, Tejero R, Cibeira MT, et al. (2015) A serum microRNA signature associated with complete response in patients with multiple myeloma. Oncotarget

99. Michon PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Parkin RK, et al (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Vol. 105, PNAS

100. Simon-Kayser B, Scoul C, Renaudin K, Jezequel P, Bouchot O, Simon-Kayser B, et al. (2015) Molecular cloning and characterization of FBXO47, a novel gene containing an F-box domain, located in the 17q12 band deleted in papillary renal carcinoma. Genes Chromosom Cancer

101. Gutiérrez NC, Sarasquete ME, Misiwiecz-Krzeminska I, Delgado M, De Las Rivas J, Ticona F V, et al. (2010) Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia

102. Leone E, Morelli E, Di Martino MT, Angiulli M, Detoma F, Guàla A, et al. (2013) Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res [Internet]. [cited 2019 Jul 18];19(8):2096–106. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23446999

103. Shen X, Guo Y, Qi J, Shi W, Wu X, Ni H, et al. (2016) Study on the association between miRNA-202 expression and drug sensitivity in multiple myeloma cells. Pathol Oncol Res [Internet]. [cited 2019 Jul 18];22(3):531–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26608580

104. Zhang J, Xiao X, Liu J (2015) The role of circulating miRNAs in multiple myeloma. Sci China Life Sci [Internet]. [cited 2019 Jul 18];58(12):1262–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26607481

105. Jung SH, Lee SE, Lee M, Kim SH, Yim SH, Kim TW, et al (2017) Circulating microRNA expressions can predict the outcome of lenalidomide plus low-dose dexamethasone treatment in patients with refractory/refractory-multiple myeloma. Haematologica

106. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, Antoniou A, Arab T, Archer F, Atkin-Smith GK, Ayre DC, Bach JM, Bachurski D, Baharvand H, Balal J, Baldacchino S, Bauer NN, Baxter AA, Beawby M, Beckham C, Bedina Zavec A, Benoussa A, Berardi AC, Bergese P, Bielska E, Blenkiron C, Bobiś-Wozowicz S, Boillard E, Boreau W, Bongiovanni A, Borrás FE, Bosch S, Boulanger CM, Breakfeld X, Breglio AM, Brennan MA, Bridgstock DR, Brisson A, Broekman ML, Bromberg JF, Bryl-Görecka P, Buch S, Buck AH, Burger D, Busatto S, Buschmann D, Bussolati B, Buzás ÉL, Byrd JB, Camussi G, Carter DR, Caruso S, Chamley LW, Chang YT, Chen C, Chen S, Cheng L, Chin AR, Clayton A, Clerici SP, Cocks A, Coccuci E, Coffey RJ, Cordeiro-da-Silva A, Couch Y, Coumans FA, Coyle B, Crescilleti R, Criado MF, D’Souza-Schorey C, Das S, Datta Chaudhuri A, de Candia P, de Santana EF, de Wever O, del Portillo H, Demaret T, Deville S, Devitt A, Dhand B, di Vizio D, Dieterich LC, Dolo V, Dominguez Rubio AP, Dominici M, Dourado MR, Driedonks TA, Duarte VF, Duncan HM, Eichemberger RM, Elmkröhn K, el Andaloussi S, Eilie-Caille C, Erdbrügger U, Falcón-Pérez JM, Fatima F, Fish JE, Flores-Bellver M, Förösinit A, Frelet-Barrand A, Frické F, Fuhrmann G, Gabriellson S, Gámiz-Valero A, Gardiner C, Gärnert K, Gaulin R, Gho YS, Giebel B, Gildel C, Gimona M, Giusti I, Goberdhan DC, Görögens A, Gorski SM, Greeving DW, Gross JC, Gulerli A, Gupta GN, Gustafson D, Handberg A, Haraszi RA, Harrison P, Hegyesi H, Hendrix A, Hill AF, Hochberg FH, Hoffmann KF, Holder B, Holtofer H, Hosseininkhani B, Hu G, Huang Y, Huber V, Hunt S, Ibrahim AG, Ikekuz T, Inal JM, Isin M, Ivanova A, Jackson HK, Jacobsen S, Jay SM, Jayachandran M, Jenster G, Jiang L, Johnson SM, Jones JC, Jong A, Jovanovic-Talisman T, Jung S, Kalluri R, Kano SI, Kaur S, Kawamura Y, Keller ET, Khamari D, Khromyakova E, Khvorova A, Kim KP, Kislinger T, Klingeborn M, Klönke DJ, Kornek M, Kosanović MM, Kovács AF, Krämer-Albers EM, Krassmann S, Krause M, Kurochkin IV, Kurochkin IV, Languino LR, Lannigan J, Lavieu K, Lázaro-Ibáñez E, le Lay S, Lee MS, Lee YXF, Lemos DS, Springer
Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Valckenborgh E Van, et al (2015) The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells. Oncotarget. 6(41)

109. Faic S, Muller J, De Veirman K, De Bruyne E, Maes K, Vrancken L, et al. (2018) Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts. Blood Cancer J.